Zacks Research Lifts Earnings Estimates for Veeva Systems

Veeva Systems Inc. (NYSE:VEEV) – Stock analysts at Zacks Research boosted their Q1 2026 EPS estimates for shares of Veeva Systems in a note issued to investors on Wednesday, March 26th. Zacks Research analyst R. Department now expects that the technology company will earn $1.21 per share for the quarter, up from their prior forecast of $1.08. The consensus estimate for Veeva Systems’ current full-year earnings is $4.35 per share. Zacks Research also issued estimates for Veeva Systems’ FY2026 earnings at $5.07 EPS, Q3 2027 earnings at $1.42 EPS, Q4 2027 earnings at $1.43 EPS, FY2027 earnings at $5.53 EPS and FY2028 earnings at $6.79 EPS.

Several other equities analysts have also recently weighed in on VEEV. Robert W. Baird raised their target price on shares of Veeva Systems from $283.00 to $285.00 and gave the company an “outperform” rating in a research note on Thursday, March 6th. Wells Fargo & Company upped their target price on Veeva Systems from $275.00 to $285.00 and gave the company an “overweight” rating in a research report on Friday, December 6th. Needham & Company LLC reaffirmed a “buy” rating and set a $270.00 price target on shares of Veeva Systems in a research report on Thursday, March 6th. JPMorgan Chase & Co. lifted their price objective on Veeva Systems from $218.00 to $249.00 and gave the company a “neutral” rating in a report on Thursday, March 20th. Finally, Royal Bank of Canada upped their price target on shares of Veeva Systems from $275.00 to $285.00 and gave the stock an “outperform” rating in a report on Friday, December 6th. Two equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and sixteen have issued a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $256.52.

Veeva Systems Stock Performance

VEEV opened at $227.74 on Monday. The business’s 50-day simple moving average is $232.01 and its 200 day simple moving average is $223.02. The firm has a market capitalization of $37.05 billion, a PE ratio of 56.23, a PEG ratio of 1.89 and a beta of 0.88. Veeva Systems has a 52-week low of $170.25 and a 52-week high of $258.93.

Hedge Funds Weigh In On Veeva Systems

A number of hedge funds have recently made changes to their positions in VEEV. Leigh Baldwin & CO. LLC bought a new position in shares of Veeva Systems in the 4th quarter worth about $685,355,000. Norges Bank acquired a new position in Veeva Systems during the 4th quarter valued at about $294,785,000. Principal Financial Group Inc. grew its holdings in Veeva Systems by 138.9% during the third quarter. Principal Financial Group Inc. now owns 2,179,284 shares of the technology company’s stock worth $457,366,000 after buying an additional 1,267,061 shares in the last quarter. JPMorgan Chase & Co. grew its stake in shares of Veeva Systems by 73.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 2,558,592 shares of the technology company’s stock worth $536,972,000 after acquiring an additional 1,081,501 shares in the last quarter. Finally, Wealthfront Advisers LLC increased its stake in Veeva Systems by 29,760.5% in the 4th quarter. Wealthfront Advisers LLC now owns 1,048,700 shares of the technology company’s stock valued at $220,489,000 after buying an additional 1,045,188 shares during the last quarter. 88.20% of the stock is currently owned by institutional investors.

Veeva Systems Company Profile

Veeva Systems Inc provides cloud-based software for the life sciences industry. It offers Veeva Commercial Cloud, a suite of software and analytics solutions, such as Veeva customer relationship management (CRM) that enable customer-facing employees at pharmaceutical and biotechnology companies; Veeva Vault PromoMats, an end-to-end content and digital asset management solution; Veeva Vault Medical that provides source of medical content across multiple channels and geographies; Veeva Crossix, an analytics platform for pharmaceutical brands; Veeva OpenData, a customer reference data solution; Veeva Link, a data application that allows link to generate real-time intelligence; and Veeva Compass includes de-identified and longitudinal patient data for the United States.